Actinium Pharmaceuticals Gets Canadian Approval for Two Patents

Dow Jones05-30 05:57

By Katherine Hamilton

Actinium Pharmaceuticals said it received approval from Canadian regulators for two patents for treatment programs.

The Canadian Intellectual Property Officer issued notices of allowances for applications for Actimab-A and Iomab-ACT.

Actimab-A works in combination with CLAG-M chemotherapy to treat the blood cancer Acute Myeloid Leukemia. A counterpart patent granted in Japan, with applications pending in the U.S. and Europe.

Iomab-ACT is designed as a targeted conditioning agent to enable adoptive cell therapies. The treatment already has a patent in the U.S., with additional applications pending in the U.S., Europe and China.

Write to Katherine Hamilton at katherine.hamilton@wsj.com

(END) Dow Jones Newswires

May 29, 2026 17:57 ET (21:57 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2639670451?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-30 05:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2639670451","market":"sh","top_or_hot":-1,"title":"Actinium Pharmaceuticals Gets Canadian Approval for Two Patents","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Katherine Hamilton \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Actinium Pharmaceuticals said it received approval from Canadian regulators for two patents for treatment programs. \n</p>\n<p>\n  The Canadian Intellectual Property Officer issued notices of allowances for applications for Actimab-A and Iomab-ACT. \n</p>\n<p>\n  Actimab-A works in combination with CLAG-M chemotherapy to treat the blood cancer Acute Myeloid Leukemia. A counterpart patent granted in Japan, with applications pending in the U.S. and Europe. \n</p>\n<p>\n  Iomab-ACT is designed as a targeted conditioning agent to enable adoptive cell therapies. The treatment already has a patent in the U.S., with additional applications pending in the U.S., Europe and China. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 29, 2026 17:57 ET (21:57 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Actinium Pharmaceuticals Gets Canadian Approval for Two Patents</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nActinium Pharmaceuticals Gets Canadian Approval for Two Patents\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-05-30 05:57</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Katherine Hamilton \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Actinium Pharmaceuticals said it received approval from Canadian regulators for two patents for treatment programs. \n</p>\n<p>\n  The Canadian Intellectual Property Officer issued notices of allowances for applications for Actimab-A and Iomab-ACT. \n</p>\n<p>\n  Actimab-A works in combination with CLAG-M chemotherapy to treat the blood cancer Acute Myeloid Leukemia. A counterpart patent granted in Japan, with applications pending in the U.S. and Europe. \n</p>\n<p>\n  Iomab-ACT is designed as a targeted conditioning agent to enable adoptive cell therapies. The treatment already has a patent in the U.S., with additional applications pending in the U.S., Europe and China. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 29, 2026 17:57 ET (21:57 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ATNM","symbol_name":"Actinium Pharmaceuticals, Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2639670451","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2639670451","pubTimestamp":1780091820,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Actinium Pharmaceuticals said it received approval from Canadian regulators for two patents for treatment programs.The Canadian Intellectual Property Officer issued notices of allowances for applications for Actimab-A and Iomab-ACT.Actimab-A works in combination with CLAG-M chemotherapy to treat the blood cancer Acute Myeloid Leukemia. A counterpart patent granted in Japan, with applications pending in the U.S. and Europe.Iomab-ACT is designed as a targeted conditioning agent to enable adoptive cell therapies. The treatment already has a patent in the U.S., with additional applications pending in the U.S., Europe and China.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ATNM":"Actinium Pharmaceuticals, Inc.","BK4139":"生物科技"},"translate_title":"Actinium Pharmaceuticals两项专利获得加拿大批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ATNM":1.5},"content_text":"By Katherine Hamilton \n\n\n \n\n\n  Actinium Pharmaceuticals said it received approval from Canadian regulators for two patents for treatment programs. \n\n\n  The Canadian Intellectual Property Officer issued notices of allowances for applications for Actimab-A and Iomab-ACT. \n\n\n  Actimab-A works in combination with CLAG-M chemotherapy to treat the blood cancer Acute Myeloid Leukemia. A counterpart patent granted in Japan, with applications pending in the U.S. and Europe. \n\n\n  Iomab-ACT is designed as a targeted conditioning agent to enable adoptive cell therapies. The treatment already has a patent in the U.S., with additional applications pending in the U.S., Europe and China. \n\n\n \n\n\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 29, 2026 17:57 ET (21:57 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.3","shortVersion":"4.42.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2639670451","isCrawlerRequest":true}